James Uthmeier

State purchasing records show a flurry of payments to private law firms hired to represent public officials scrutinized by a grand jury.

Florida and New Mexico were the two states that did not join an otherwise nationwide, $18 billion settlement earlier this year with Meta in response to allegations the company intentionally created and profited from developing for young users "addictive features."

Gov. Ron DeSantis praised the decision by the 1st District Court of Appeal, which asserted a $10 million settlement arrangement from Medicaid provider Centene to the Hope Florida Foundation was legal.

Despite the finding that the funds from the settlement were misappropriated, the report didn’t indict anyone, citing insufficient evidence.

The take included protected sea turtles and their hatchlings, he says.

The Internal Revenue Service is reviewing a whistleblower claim about $10 million in Medicaid settlement money that moved through the Hope Florida Foundation and, within weeks, into a political committee chaired by James Uthmeier, now Florida's attorney general, according to new records obtained by the Florida Trident.

The letter reveals four separate investigations. All are closed except for one grievance, filed on Sept. 11.

Terrorism labels were applied to a series of groups, including CAIR, the Muslim Brotherhood and the antifa movement. The ACLU, representing CAIR-Florida, will file for a preliminary injunction.

The grandchild of a DeSantis appointee appears to be at the center of complaints against a teacher whom Attorney General James Uthmeier publicly accused of mistreating an student over his political views.

The filing is part of the original case Uthmeier filed against OpenAI on June 1, after he previously began a probe into the company that was expanded to look at possible criminal charges.

One school board member says the investigations have a chilling effect on teachers throughout the district.

According to the complaint, defendants benefited financially after manufacturers inflated prices for insulin and related meds, then paid rebates to PBMs in exchange for preferred formulary placement.